Market capitalization | $45.49m |
Enterprise Value | $-105.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.38 |
EV/Sales (TTM) EV/Sales | -1.97 |
P/S ratio (TTM) P/S ratio | 0.85 |
P/B ratio (TTM) P/B ratio | 0.30 |
Revenue growth (TTM) Revenue growth | 4.58% |
Revenue (TTM) Revenue | $53.48m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
4 Analysts have issued a Repare Therapeutics Inc forecast:
4 Analysts have issued a Repare Therapeutics Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | 53 53 |
5%
5%
|
|
Gross Profit | 52 52 |
8%
8%
|
|
EBITDA | -90 -90 |
19%
19%
|
EBIT (Operating Income) EBIT | -92 -92 |
20%
20%
|
Net Profit | -85 -85 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.
Head office | Canada |
CEO | Lloyd Segal |
Employees | 129 |
Founded | 2016 |
Website | www.reparerx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.